Publications by authors named "Michelle D Hoarty"

Claim this Profile
Z
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D Hoarty, Rohit Vyasamneni

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D Hoarty, Rohit Vyasamneni

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
Miriam L Fichtner, Michelle D Hoarty, Douangsone D Vadysirisack, Bailey Munro-Sheldon, Richard J Nowak

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis